Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST266 in Dry Eye
NCT02369861Phase 1Completed
- Sponsor
- Noveome Biotherapeutics
- Start
- Mar 2015
- Primary completion
- Oct 2015
- Modality
- Cytokines & Interferons, Hormones & Growth Factors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ST266 in dry eye syndrome (DED) (2 arms), sponsored by Noveome Biotherapeutics. Primary endpoint: Corneal staining with fluorescein at 6 weeks. Started Mar 2015; status: completed.
02
Drugs
ST266
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02369861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02369861.